EUVIMEDEUVIMED entdecken
Crossref

Incidence and Survival of Patients With Angioimmunoblastic T‐Cell Lymphoma: A Nationwide Population‐Based Study Using English Cancer Registration Data

Sarah J Halligan iD, Christopher P Fox, Matthew J Grainge, Mark J Bishton iD

Hematological Oncology · 2026-05 · 44 (3)

DOI: 10.1002/hon.70199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 18.05.2026. Verfasst von Sarah J Halligan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK. Hauptthemen laut MEDLINE: Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Nottingham University Hospitals Charity Lymphoma Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angioimmunoblastic T‐cell lymphoma (AITL) is a rare, aggressive subtype of peripheral T‐cell lymphoma. Whole population studies of AITL are infrequent and often grouped along with other T‐cell lymphomas. We undertook a population‐based study using ICD‐O3‐coded cases of AITL diagnosed 2013–2019 in order to establish AITL epidemiology in England, along with survival outcomes and associated diagnoses. We identified 993 cases, with a median age of 71 years. Overall incidence was 2.57 cases/million person‐years (95% CI 2.41–2.74). The incidence increased with age, ranging from 0.24 cases/million person‐years at 0–49 years (CI 0.19–0.31) to 11.56 in ≥ 70 years (CI 10.62–12.55), and was lower in females (incidence rate ratio [IRR] 0.74, CI 0.66–0.84). One and 3‐year overall survival (OS) were 58% and 37% respectively. 151 patients received auto‐SCT, with a 1‐year and 3‐year OS from transplant of 78.9% and 65.8%. In multivariable analysis, gender (hazard ratio [HR] in females = 0.77, 95% CI 0.66–0.90) and age (HR in ≥ 80 years = 4.41, CI 2.86–6.79) impacted OS. 142 patients developed an associated B‐cell lymphoma or Hodgkin lymphoma (14.3%). A diagnosis of autoimmune hemolytic anemia (AIHA) was reported in 56 patients (5.6%), and immune thrombocytopenic purpura (ITP) in 14 (1.4%). Our study defines AITL incidence for the first time in England, confirms OS in an unselected population, and describes rates of autoimmune disease and B‐cell lymphomas. Gender and age are the primary characteristics that influence outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoblastic LymphadenopathyLymphoma, T-Cell, PeripheralLymphoma, T-CellHumansFemaleMaleIncidenceAgedMiddle AgedAged, 80 and overAdultAdolescentEnglandYoung AdultChildRegistriesInfantChild, PreschoolSurvival RateInfant, Newborn

Stichwörter der Autor:innen

angioimmunoblastic T‐cell lymphoma (AITL)chemotherapyincidenceperipheral T‐cell lymphomaprognosis

Autor:innen und Institutionen

  • Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID-Profile: Sarah J Halligan, Mark J Bishton

Förderung

  • Nottingham University Hospitals Charity Lymphoma Research Fund

Zitieren

APA

Halligan, S. J., Fox, C. P., Grainge, M. J., & Bishton, M. J. (2026). Incidence and Survival of Patients With Angioimmunoblastic T‐Cell Lymphoma: A Nationwide Population‐Based Study Using English Cancer Registration Data. Hematological Oncology, 44(3). https://doi.org/10.1002/hon.70199

Vancouver

Halligan SJ, Fox CP, Grainge MJ, Bishton MJ. Incidence and Survival of Patients With Angioimmunoblastic T‐Cell Lymphoma: A Nationwide Population‐Based Study Using English Cancer Registration Data. Hematological Oncology. 2026;44(3). doi:10.1002/hon.70199

BibTeX
@article{Halligan2026,
  author = {Halligan, Sarah J and Fox, Christopher P and Grainge, Matthew J and Bishton, Mark J},
  title = {Incidence and Survival of Patients With Angioimmunoblastic T‐Cell Lymphoma: A Nationwide Population‐Based Study Using English Cancer Registration Data},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  doi = {10.1002/hon.70199}
}
Kostenlos starten →